Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
EBIT MarginEBITDA MarginEBT MarginNet MarginOperating MarginReturn on Sales

ProQR Therapeutics (PRQR) EBITDA Margin (2021 - 2025)

Historic EBITDA Margin for ProQR Therapeutics (PRQR) over the last 5 years, with Q3 2025 value amounting to 382.69%.

  • ProQR Therapeutics' EBITDA Margin rose 1618900.0% to 382.69% in Q3 2025 from the same period last year, while for Sep 2025 it was 162.34%, marking a year-over-year increase of 927000.0%. This contributed to the annual value of 146.58% for FY2024, which is 3039300.0% up from last year.
  • According to the latest figures from Q3 2025, ProQR Therapeutics' EBITDA Margin is 382.69%, which was up 1618900.0% from 336.94% recorded in Q2 2025.
  • In the past 5 years, ProQR Therapeutics' EBITDA Margin registered a high of 8668.09% during Q1 2021, and its lowest value of 7565.69% during Q4 2021.
  • Moreover, its 5-year median value for EBITDA Margin was 231.25% (2025), whereas its average is 756.51%.
  • Within the past 5 years, the most significant YoY rise in ProQR Therapeutics' EBITDA Margin was 59390200bps (2022), while the steepest drop was -74384400bps (2022).
  • Quarter analysis of 5 years shows ProQR Therapeutics' EBITDA Margin stood at 7565.69% in 2021, then soared by 78bps to 1626.67% in 2022, then soared by 88bps to 190.86% in 2023, then dropped by -23bps to 234.06% in 2024, then soared by 263bps to 382.69% in 2025.
  • Its EBITDA Margin stands at 382.69% for Q3 2025, versus 336.94% for Q2 2025 and 231.25% for Q1 2025.